VNA
UTHR icon

Valley National Advisers’s United Therapeutics UTHR Stock Holding History

Valley National Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25K Hold
6
– – ﹤0.01% 752
2026
Q1 		$3K Hold
6
– – ﹤0.01% 750
2025
Q4 		$2K Hold
6
– – ﹤0.01% 807
2025
Q3 		$2K Hold
6
– – ﹤0.01% 754
2025
Q2 		$1K Hold
6
– – ﹤0.01% 805
2025
Q1 		$1K Hold
6
– – ﹤0.01% 807
2024
Q4 		$2K Buy
+6
New +$2.21K ﹤0.01% 698

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Valley National Advisers's UTHR Position: Q2 2026 in Review

Valley National Advisers held its United Therapeutics (UTHR) position steady in Q2 2026 at 6 shares worth $3.25K. The position accounts for ﹤0.01% of the portfolio, ranked #752.

Valley National Advisers first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Valley National Advisers held 6 shares of United Therapeutics worth $3.25K as of Q2 2026.
  • Valley National Advisers left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Valley National Advisers's portfolio in Q2 2026, its #752 holding.
  • Valley National Advisers first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.